Recombinant COVID-19 vaccine (Sf9 cell)

BIOLOGICAL4 trials

Sponsors

WestVac Biopharma Co., Ltd.

Conditions

COVID-19SARS-CoV-2 InfectionSARS-CoV-2 Pneumonia

Phase 2

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

CompletedNCT05463354

WestVac Biopharma Co., Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-07-11End: 2024-01-26Updated: 2024-04-24

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

CompletedNCT05770180

WestVac Biopharma Co., Ltd.COVID-19

Start: 2023-03-30End: 2024-04-09Updated: 2024-07-24

Unknown Phase

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

CompletedNCT05465785

WestVac Biopharma Co., Ltd.COVID-19, SARS-CoV-2 Pneumonia

Start: 2022-07-20End: 2023-12-30Updated: 2024-04-24

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

CompletedNCT06381843

WestVac Biopharma Co., Ltd.COVID-19, SARS-CoV-2 Infection

Start: 2022-08-02End: 2023-12-30Updated: 2024-04-25